The City of Amarillo has announced they will now be providing Sotrovimab to patients at the Amarillo Infusion Center.
This is due to a new direction from the Centers for Disease Control and Prevention and the Texas Department of State Health Services.
Sotrovimab will replace Bamlanivimab and Regeneron as treatment for Covid-19 patients who are eligible for treatment at the infusion center, located at 808 South Johnson Street.
The infusion center uses a prioritization method for treatment for the most vulnerable patients as supplies remain limited.
The City says Sotrovimab is deemed more effective against the Omicron variant.